Bone Mineral Density News and Research

RSS

3M, Radius collaborate to develop BA058 for treatment of osteoporosis

Radius Health, Inc. and 3M Drug Delivery Systems today announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP analog, for the treatment of osteoporosis.

24 May 2011

Osteoarthritis directly linked to low-fat, high-carb food

Osteoarthritis is a degenerative joint disease and the most common cause of disability today. It was once considered a problem of the old but it is now commonly diagnosed in those as young as the mid-twenties and early thirties. According to the Arthritis Foundation, about four million, quality-adjusted life years are lost due to knee osteoarthritis alone.

20 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

New autism research findings presented at 10th annual IMFAR

Much about autism is unknown, but researchers from the University of Rochester Medical Center (URMC) are working to learn more about the neurodevelopmental disorder and its most effective treatments. A team of researchers from URMC joins researchers from across the world in San Diego this week for the 10th annual International Meeting for Autism Research (IMFAR).

16 May 2011

$Study: Only 15% of heart failure patients with spinal fractures are being treated for osteoporosis$

Study: Only 15% of heart failure patients with spinal fractures are being treated for osteoporosis

One in 10 heart failure patients had compression fractures in the spine that could have been detected by a chest X-ray, but few are receiving treatment to help prevent such fractures according to a Canadian study published in the American Heart Association journal Circulation: Heart Failure.

11 May 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

Calcium and vitamin D intake before bone density test can reduce risk of osteoporosis

Has a bone density scan placed you at risk for osteoporosis, leading your doctor to prescribe a widely advertised bone-building medication? Not so fast! A University of Illinois study finds that an effective first course of action is increasing dietary calcium and vitamin D or taking calcium and vitamin D supplements.

3 May 2011

$Hyponatremia linked to high risk of fractures in elderly patients$

Hyponatremia linked to high risk of fractures in elderly patients

A common blood disorder, hyponatremia, may be a risk factor for fractures in elderly patients, new research presented at the European Congress of Endocrinology shows.

3 May 2011

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

28 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

Study: Diet-exercise can improve physical performance in obese seniors

For obese seniors, dieting and exercise together are more effective at improving physical performance and reducing frailty than either alone.

31 Mar 2011

Study: Gene combinations may increase risk of hip osteoporosis in women

Women with osteoporosis in their hip suffer menopause two years earlier than healthy women, a study conducted at the University of Granada says. Additionally, although further study is required, researchers have found at least three genetic markers associated with osteoporosis in the hip in postmenopausal women.

30 Mar 2011

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

25 Mar 2011

$Falls history improves accuracy of fracture prediction models$

Falls history improves accuracy of fracture prediction models

Researchers from the MRC Lifecourse Epidemiology Unit in Southampton, UK, have presented a new study that shows how the inclusion of falls history, in addition to clinical risk factors (CRFs) and bone mineral density (BMD) values, would greatly improve the accuracy of fracture prediction models. The research findings were presented today at the European Congress on Osteoporosis & Osteoarthritis in Valencia, Spain.

25 Mar 2011

Electromagnetic radiation from cellular phones may affect bone strength

Electromagnetic radiation from cellular phones may adversely affect bone strength, suggests a study in the March Journal of Craniofacial Surgery. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

25 Mar 2011

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, positive top-line results.

25 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.

16 Mar 2011

$HIV infection and increased fracture risk: Study$

HIV infection and increased fracture risk: Study

According to a latest study, adults between ages 25 and 54 infected with HIV, are at increased risk for bone fractures compared to the general population. Until now it was known that low bone mineral density was common in people with HIV, but no concrete proof existed.

14 Mar 2011

$HIV-infected patients may face increased risk of bone fracture$

HIV-infected patients may face increased risk of bone fracture

Low bone mineral density in HIV-infected patients is common and raises concerns about increased risks of fracture. Although there have been several studies regarding bone mineral density, there have been few data on rates of fracture in this population.

11 Mar 2011

Bone Mineral Density News and Research

3M, Radius collaborate to develop BA058 for treatment of osteoporosis

Osteoarthritis directly linked to low-fat, high-carb food

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

New autism research findings presented at 10th annual IMFAR

Study: Only 15% of heart failure patients with spinal fractures are being treated for osteoporosis

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Calcium and vitamin D intake before bone density test can reduce risk of osteoporosis

Hyponatremia linked to high risk of fractures in elderly patients

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Study: Diet-exercise can improve physical performance in obese seniors

Study: Gene combinations may increase risk of hip osteoporosis in women

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Falls history improves accuracy of fracture prediction models

Electromagnetic radiation from cellular phones may affect bone strength

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

HIV infection and increased fracture risk: Study

HIV-infected patients may face increased risk of bone fracture

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News